Connect Biopharma Q2 2026: $31.5M Cash, R&D Surge, and Insider Trading Plans
CNTB sits 92% above its 52-week low of $1.23.
Summary
Connect Biopharma reported a wider Q2 loss on higher R&D spending, with $31.5M in cash providing a one-year runway. Two executives adopted 10b5-1 plans to sell up to 477,591 shares.
Key Events · Earnings and Guidance · CNTB
-
Q2 Net Loss Widens on R&D Surge
Net loss was $17.3M for Q2 2026, up from $12.9M a year ago, as R&D expense nearly doubled to $16.3M to support rademikibart Phase 2 trials.
-
Cash Runway of at Least One Year
Cash, equivalents, and short-term investments totaled $31.5M as of June 30, 2026, which management believes funds operations for at least one year.
-
Insider Trading Plans Adopted
President David Szekeres and SVP Finance Lisa Peraza adopted Rule 10b5-1 plans on June 12, 2026, covering up to 400,000 and 77,591 shares respectively, with sales starting after cooling-off periods.
-
Simcere Milestone Update
A $7M regulatory milestone was achieved in Q2, but a $4M time-based milestone lapsed. Remaining eligible milestones total approximately $99M.
Analysis · CNTB · Life Sciences
A net loss of $17.3 million in Q2 2026 reflects a near-doubling of R&D expense to $16.3 million as rademikibart advances through Phase 2 trials. Cash and investments of $31.5 million are expected to fund operations for at least one year, according to management. The filing also discloses that the President and SVP Finance adopted Rule 10b5-1 trading plans in June, permitting combined sales of up to 477,591 shares over the next year and adding potential selling pressure. On the licensing front, a $7 million regulatory milestone from Simcere was achieved, while a $4 million time-based milestone lapsed, leaving $99 million in potential future milestones.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.4% of the 1637 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNTB was trading at $2.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $146.7M. The 52-week trading range was $1.23 to $3.82. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.